ReviewTrends in biotechnology2017
Optogenetic Immunomodulation: Shedding Light on Antitumor Immunity.
Review in Trends in biotechnology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed.
- A single-component optogenetic toolkit for reversible visualization and programmable control of microtubule dynamics.Cell reports methods · 2026Article
- Illuminating cancer therapy: The translational path of optogenetics.Bioactive materials · 2026Review
- Engineering of genetically encoded programmable calcium channel inhibitory binders.Nature communications · 2026Article
- Optogenetics for Investigating and Targeting Hallmark Traits of Cancer.Biomolecules · 2026Review
- Neuro-Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets.MedComm · 2026Review
- Thermally Controlled State Switches for Engineered Macrophages.ACS synthetic biology · 2025Article
- Optogenetic engineering for precision cancer immunotherapy.Trends in pharmacological sciences · 2025Review
- Optogenetic control of T cells for immunomodulation.Essays in biochemistry · 2025Review
- A second photoactivatable state of the anion-conducting channelrhodopsin GtACR1 empowers persistent activity.Communications biology · 2025Article
- A Comprehensive Analysis of Epoxide Hydrolase 2 (EPHX2) in Pan-Cancer.Cancer reports (Hoboken, N.J.) · 2025Article
- Multimodal Key Anti-Oncolytic Therapeutics Are Effective In Cancer Treatment?International journal of nanomedicine · 2025Review
- The current landscape of optogenetics for the enhancement of adoptive T-cell therapy.Discovery immunology · 2025Review
- Ultrasound-mediated spatial and temporal control of engineered cells in vivo.Nature communications · 2024Article
- Engineered nanoparticles for precise targeted drug delivery and enhanced therapeutic efficacy in cancer immunotherapy.Acta pharmaceutica Sinica. B · 2024Review
- Application of Optogenetics in Neurodegenerative Diseases.Cellular and molecular neurobiology · 2024Review
- Pan-cancer analysis shows that BCAP31 is a potential prognostic and immunotherapeutic biomarker for multiple cancer types.Frontiers in immunology · 2024Article
- Mechanobiological Strategies to Augment Cancer Treatment.ACS omega · 2023Review
- Optogenetic engineering of STING signaling allows remote immunomodulation to enhance cancer immunotherapy.Nature communications · 2023Article
- Optogenetics Sheds Light on Brown and Beige Adipocytes.Journal of cellular signaling · 2023Article
- Optogenetics for transcriptional programming and genetic engineering.Trends in genetics : TIG · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Microbial opsin-based optogenetic tools have been transformative for neuroscience. To extend optogenetic approaches to the immune system to remotely control immune responses with superior spatiotemporal precision, pioneering tools have recently been crafted to modulate lymphocyte trafficking, inflammasome activation, dendritic cell (DC) maturation, and antitumor immunity through the photoactivation of engineered chemokine receptors and calcium release-activated calcium channels. We highlight herein some conceptual design strategies for installing light sensitivities into the immune signaling network and, in parallel, we propose potential solutions for in vivo optogenetic applications in living organisms with near-infrared light-responsive upconversion nanomaterials. Moreover, to move beyond proof-of-concept into translational applications, we discuss future prospects for integrating personalized immunoengineering with optogenetics to overcome critical hurdles in cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.